Clinical Trial Update: Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of Salinosporamide A (NPI-0052) in patients with advanced cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Salinosporamide A (salinosporamide A)

Snippet

Sponsor: Celgene | Conditions: Advanced Cancer | Phase 1 | Status: COMPLETED